<?xml version='1.0' encoding='utf-8'?>
<document id="25889173"><sentence text="A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine."><entity charOffset="167-177" id="DDI-PubMed.25889173.s1.e0" text="pregabalin" /><entity charOffset="181-191" id="DDI-PubMed.25889173.s1.e1" text="duloxetine" /><pair ddi="false" e1="DDI-PubMed.25889173.s1.e0" e2="DDI-PubMed.25889173.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25889173.s1.e0" e2="DDI-PubMed.25889173.s1.e1" /></sentence><sentence text="Anticipating and controlling drug-drug interactions (DDIs) in older patients with painful diabetic peripheral neuropaty (pDPN) presents a significant challenge to providers" /><sentence text=" The purpose of this study was to examine the impact of newly initiated pregabalin or duloxetine treatment on Medicare Advantage Prescription Drug (MAPD) plan pDPN patients' encounters with potential drug-drug interactions, the healthcare cost and utilization consequences of those interactions, and opioid utilization"><entity charOffset="72-82" id="DDI-PubMed.25889173.s3.e0" text="pregabalin" /><entity charOffset="86-96" id="DDI-PubMed.25889173.s3.e1" text="duloxetine" /><pair ddi="false" e1="DDI-PubMed.25889173.s3.e0" e2="DDI-PubMed.25889173.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25889173.s3.e0" e2="DDI-PubMed.25889173.s3.e1" /></sentence><sentence text="" /><sentence text="Study subjects required a pregabalin or duloxetine pharmacy claim between 07/01/2008-06/30/2012 (index event), ≥1 inpatient or ≥2 outpatient medical claims with pDPN diagnosis between 01/01/2008-12/31/2012, and ≥12 months pre- and ≥6 post-index enrollment"><entity charOffset="26-36" id="DDI-PubMed.25889173.s5.e0" text="pregabalin" /><entity charOffset="40-50" id="DDI-PubMed.25889173.s5.e1" text="duloxetine" /><pair ddi="false" e1="DDI-PubMed.25889173.s5.e0" e2="DDI-PubMed.25889173.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25889173.s5.e0" e2="DDI-PubMed.25889173.s5.e1" /></sentence><sentence text=" Propensity score matching was used to balance the pregabalin and duloxetine cohorts on pre-index demographics and comorbidities"><entity charOffset="51-61" id="DDI-PubMed.25889173.s6.e0" text="pregabalin" /><entity charOffset="66-76" id="DDI-PubMed.25889173.s6.e1" text="duloxetine" /><pair ddi="false" e1="DDI-PubMed.25889173.s6.e0" e2="DDI-PubMed.25889173.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25889173.s6.e0" e2="DDI-PubMed.25889173.s6.e1" /></sentence><sentence text=" Potential DDIs were defined by Micromedex 2" /><sentence text="0 and identified by prescription claims" /><sentence text=" Six-month post-index healthcare utilization (HCU) and costs were calculated using pharmacy and medical claims" /><sentence text="" /><sentence text="No significant differences in pre-index demographics or comorbidities were found between pregabalin subjects (n = 446) and duloxetine subjects (n = 446)"><entity charOffset="89-99" id="DDI-PubMed.25889173.s11.e0" text="pregabalin" /><entity charOffset="123-133" id="DDI-PubMed.25889173.s11.e1" text="duloxetine" /><pair ddi="false" e1="DDI-PubMed.25889173.s11.e0" e2="DDI-PubMed.25889173.s11.e0" /><pair ddi="false" e1="DDI-PubMed.25889173.s11.e0" e2="DDI-PubMed.25889173.s11.e1" /></sentence><sentence text=" Potential DDI prevalence was significantly greater (p &lt; 0" /><sentence text="0001) among duoxetine subjects (56"><entity charOffset="12-21" id="DDI-PubMed.25889173.s13.e0" text="duoxetine" /></sentence><sentence text="7%) than among pregabalin subjects (2"><entity charOffset="15-25" id="DDI-PubMed.25889173.s14.e0" text="pregabalin" /></sentence><sentence text="9%)" /><sentence text=" There were no significant differences in HCU or costs between pregablin subjects with and without a potential DDI"><entity charOffset="63-72" id="DDI-PubMed.25889173.s16.e0" text="pregablin" /></sentence><sentence text=" By contrast, duloxetine subjects with a potential DDI had higher mean all-cause costs ($13,908 vs"><entity charOffset="14-24" id="DDI-PubMed.25889173.s17.e0" text="duloxetine" /></sentence><sentence text=" $9,830; p = 0" /><sentence text="001), more subjects with ≥1 inpatient visits (35" /><sentence text="6% vs 25" /><sentence text="4%; p = 0" /><sentence text="02), and more subjects with ≥1 emergency room visits (32" /><sentence text="8% vs" /><sentence text=" 20" /><sentence text="7%; p = 0" /><sentence text="005) in comparison to duloxetine subjects without a potential DDI"><entity charOffset="22-32" id="DDI-PubMed.25889173.s26.e0" text="duloxetine" /></sentence><sentence text=" There was a trend toward a difference between pregabalin and duloxetine subjects in their respective pre-versus-post differences in milligrams (mg) of morphine equivalents/30 days used (60"><entity charOffset="47-57" id="DDI-PubMed.25889173.s27.e0" text="pregabalin" /><entity charOffset="62-72" id="DDI-PubMed.25889173.s27.e1" text="duloxetine" /><entity charOffset="152-160" id="DDI-PubMed.25889173.s27.e2" text="morphine" /><pair ddi="false" e1="DDI-PubMed.25889173.s27.e0" e2="DDI-PubMed.25889173.s27.e0" /><pair ddi="false" e1="DDI-PubMed.25889173.s27.e0" e2="DDI-PubMed.25889173.s27.e1" /><pair ddi="false" e1="DDI-PubMed.25889173.s27.e0" e2="DDI-PubMed.25889173.s27.e2" /><pair ddi="false" e1="DDI-PubMed.25889173.s27.e1" e2="DDI-PubMed.25889173.s27.e1" /><pair ddi="false" e1="DDI-PubMed.25889173.s27.e1" e2="DDI-PubMed.25889173.s27.e2" /></sentence><sentence text="2 mg and 176" /><sentence text="9 mg, respectively; p = 0" /><sentence text="058)" /><sentence text="" /><sentence text="The significantly higher prevalence of potential DDIs and potential cost impact found in pDPN duloxetine users, relative to pregabalin users, underscore the importance of considering DDIs when selecting a treatment"><entity charOffset="94-104" id="DDI-PubMed.25889173.s32.e0" text="duloxetine" /><entity charOffset="124-134" id="DDI-PubMed.25889173.s32.e1" text="pregabalin" /><pair ddi="false" e1="DDI-PubMed.25889173.s32.e0" e2="DDI-PubMed.25889173.s32.e0" /><pair ddi="false" e1="DDI-PubMed.25889173.s32.e0" e2="DDI-PubMed.25889173.s32.e1" /></sentence><sentence text="" /></document>